Search results (1331)
« Back to PublicationsA STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D)
Suttle B. et al, (2014), CLINICAL PHARMACOLOGY & THERAPEUTICS, 95, S89 - S90
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M. et al, (2014), J Med Chem, 57, 1531 - 1542
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Valle JW. et al, (2014), J Clin Oncol, 32, 504 - 512
Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate.
Grover A. et al, (2014), J Exp Med, 211, 181 - 188
Discovery of prognostic and predictive tissue biomarkers in patients with resectable esophageal cancer
MacGregor TP. et al, (2014), JOURNAL OF CLINICAL ONCOLOGY, 32
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.
Payne MJ. et al, (2014), J Clin Oncol, 32, 185 - 190
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Stavraka C. et al, (2014), Cancer, 120, 262 - 270
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Corrie PG. et al, (2014), The Lancet Oncology, 15, 620 - 630
Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
Blagden S. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, 7 - 7
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.
Pinato DJ. et al, (2014), PLoS One, 9
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: Current and future perspectives in adult and paediatric disease
Eyre TA. et al, (2014), European Journal of Haematology
Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect
Eyre TA. et al, (2014), International Journal of Hematology, 1 - 3
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.
Collins GP. et al, (2014), Br J Haematol, 164, 39 - 52
Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012)
Sims MC. et al, (2014), British Journal of Haematology
Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia
Harrison CN. et al, (2014), British Journal of Haematology, 167, 421 - 423
NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival
Ghazaly EA. et al, (2014), CANCER RESEARCH, 74
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W. et al, (2014), J Natl Cancer Inst, 106
Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest
Eyre TA. et al, (2014), Transfusion, 54, 1231 - 1234
T-cell/histiocyte-rich large B-cell lymphoma - transformation of Nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow
Eyre TA. et al, (2014), European Journal of Haematology, 92, 550 - 551